Učitavanje...
DRUG EVALUATION: Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis
INTRODUCTION: Vedolizumab is an anti-integrin approved for the treatment of Crohn’s disease and ulcerative colitis. By binding the α4β7-integrin heterodimer, vedolizumab blocks leukocyte translocation into gastrointestinal tissue. AREAS COVERED: This review discusses the chemistry, pharmacologic pro...
Spremljeno u:
| Izdano u: | Expert Opin Drug Metab Toxicol |
|---|---|
| Glavni autori: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2016
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4917449/ https://ncbi.nlm.nih.gov/pubmed/27096357 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/17425255.2016.1181171 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|